Efficacy and safety of α1-adrenergic receptor antagonists in managing acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials.

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of α1-adrenergic receptor antagonists in managing acute urinary retention (AUR) due to benign prostatic hyperplasia (BPH). Involving 8 randomized controlled trials, the study found that these antagonists significantly increased the success rate of trial without catheter (TWOC) by 24.5% compared to placebo (95% CI: 18.4-30.7, p < 0.0001).

Key findings

• α1-adrenergic receptor antagonists improved TWOC success by 24.5% compared to placebo.
• The pooled analysis included 8 randomized controlled trials.
• No significant increase in adverse events was observed with α1-blocker therapy.
• The incidence of AUR is approximately 6.8 episodes per 1,000 individuals per year.

Why it matters

The findings suggest that α1-adrenergic receptor antagonists can enhance short-term voiding success in men experiencing AUR due to BPH, potentially improving patient outcomes and reducing the need for catheterization.